Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

Breast |  Gastrointestinal |  Head and Neck |  Hematology |  Leukemia |  Lung |  Lymphoma |  Myelomas |  Prostate |  Renal |  Solid Tumors |

Breast

Gastrointestinal

  • Keytruda vs. Investigator's Choice for 2nd line Esophageal
    A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy

Head and Neck

Hematology

Leukemia

Lung

Lymphoma

Myelomas

Prostate

Renal

Solid Tumors